AZN — ASTRAZENECA PLC
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 901832 ·
United Kingdom
Last close
$182.27
Market Cap
$282.68B
52W High
$210.52
52W Low
$153.41
ADV30
2,998,812
Next earnings
2026-10-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 16,209,000,000 | 13,263,000,000 | 4,387,000,000 | 3,117,000,000 | 119,922,000,000 | 7,936,000,000 | 68,108,000,000 |
| Jun 2026 | 15,384,000,000 | 12,861,000,000 | 3,164,000,000 | 2,507,000,000 | 115,833,000,000 | 4,893,000,000 | 65,463,000,000 |
| Mar 2026 | 15,288,000,000 | 12,610,000,000 | 4,246,000,000 | 3,080,000,000 | 114,015,000,000 | 7,560,000,000 | 66,631,000,000 |
| Dec 2025 | 15,503,000,000 | 12,385,000,000 | 2,978,000,000 | 2,326,000,000 | 114,074,000,000 | 5,711,000,000 | 65,355,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$13,232,000,000
Investing CF
$-8,035,000,000
Financing CF
$-5,348,000,000
CapEx
$-7,135,000,000
Dividends Paid
$-4,958,000,000
Buybacks
—
EPS Diluted TTM
$7.07
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$14,069,000,000
Inventory
$6,883,000,000
Receivables
—
ST Investments
$230,000,000
EBIT TTM
$15,089,000,000
Pretax Income TTM
$13,300,000,000
Interest Exp TTM
$1,789,000,000
Analysts
12
Yahoo Snapshot (yfinance, live)
Total Revenue
$61,366,001,664
EBITDA
$19,904,000,000
Free Cash Flow
$4,905,375,232
Enterprise Value
$275,880,673,280
Total Cash
$4,968,000,000
Total Debt
$32,349,999,104
Shares Out
1,550,895,914
Trailing EPS
$6.68
Book Value
$32.43
ROE
22.0%
ROA
8.0%
Div Yield
2.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 58,739,000,000 | 13,327,000,000 | 10,225,000,000 | 114,074,000,000 | 65,355,000,000 | 48,667,000,000 | 14,575,000,000 |
| Dec 2024 | 54,073,000,000 | 10,251,000,000 | 7,035,000,000 | 104,035,000,000 | 63,164,000,000 | 40,786,000,000 | 11,861,000,000 |
| Dec 2023 | 45,811,000,000 | 8,722,000,000 | 5,955,000,000 | 101,119,000,000 | 61,953,000,000 | 39,143,000,000 | 10,345,000,000 |
| Dec 2022 | 44,351,000,000 | 4,512,000,000 | 3,288,000,000 | 96,483,000,000 | 59,425,000,000 | 37,037,000,000 | 9,808,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$11.36
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVS | NOVARTIS AG | $302.46B | $159.13 | — |
| MRK | Merck & Co., Inc. | $353.44B | $143.37 | — |
| ABT | ABBOTT LABORATORIES | $181.35B | $104.71 | — |
| PFE | PFIZER INC | $162.27B | $28.47 | — |
| ABBV | AbbVie Inc. | $517.59B | $292.82 | — |
News headlines (Yahoo Finance, 1h cache)
AstraZeneca gets Jefferies backing as broker sees $80bn sales target within reach
2026-11-18 15:30 · Yahoo
The Zacks Analyst Blog Highlights AstraZeneca, Linde, Eaton, Franklin and BV Financial
2026-11-18 10:43 · Yahoo
AstraZeneca Stock Up 12% in a Month: Time to Buy, Sell or Hold?
2026-11-17 14:58 · Yahoo
AstraZeneca Bet $2 Billion on Summit’s Cancer Drug. The FDA Just Said Not Yet.
2026-11-16 16:37 · Yahoo
AstraZeneca Secures US, EU Nod for New Myasthenia Gravis Drug Klygefa
2026-11-16 16:02 · Yahoo
Is AstraZeneca (LSE:AZN) Reasonable After Its Oncology Led Cash Flow Push?
2026-11-14 01:11 · Yahoo
AstraZeneca (LSE:AZN) Will Transfer Its Primary Listing To The NYSE In 2026
2026-11-14 00:24 · Yahoo
Summit Therapeutics (SMMT) Stock Sees Modest Fair Value Cut As Analysts Weigh Trial Risks
2026-11-17 11:14 · Yahoo
Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene Editing ...
2026-11-13 23:03 · Yahoo
FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
2026-11-18 14:21 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.